MADRID – October 28, 2026 -- Hengrui Pharma presented a record 64 oncology studies at the ESMO Congress 2026 in Madrid. Innovative oncology medicines generated 81.02% of the company's innovative medicine sales revenue in 2025.
Hengrui lists 64 accepted studies across 21 drugs
The accepted work comprises three Proffered Papers, three Rapid Oral presentations, 32 Posters and 26 e-Posters. The studies span more than ten cancer areas, including gastrointestinal, lung, breast, gynecological and genitourinary cancers, plus supportive care. They involve 21 innovative drugs in China: nine approved products and 12 investigational candidates.
Hengrui has attended ESMO for 11 consecutive years since 2016. It has presented nearly 200 research findings at the congress since 2023.
Hengrui Oncology has 14 Class 1 medicines approved in China and about 50 assets in the clinic
As of June 2026, 14 independently developed Class 1 innovative oncology medicines had been approved for marketing in China. The portfolio covers seven major disease areas plus oncology supportive care. Around 50 innovative assets are in clinical development, with around 100 clinical studies underway worldwide. Several products have received U.S. FDA Orphan Drug and Fast Track designations.
Hengrui's R&D approach has four parts: precision therapy, immunotherapy, targeted therapy and supportive care. Alongside established platforms such as antibody-drug conjugates (ADCs), the company is exploring AI-driven drug discovery (AIDD) to improve R&D efficiency.
Hengrui operates 15 R&D sites and pursues out-licensing, co-development and NewCo deals
The company runs 15 R&D sites across Asia, Europe, North America, Australia and other key markets. It is advancing international multicenter clinical trials for multiple programs and building R&D and regulatory capabilities in major global markets. Its collaboration models include out-licensing, co-development and NewCo partnerships, aimed at accelerating the expansion of its therapies into overseas markets.
Dr Karen Atkin, Head of Global Business and Portfolio Strategy at Hengrui Pharma, said the company will continue its international development strategy and "expand opportunities to develop our innovative medicines in partnership with international collaborators."